A suramin derivative induces enterocyte-like differentiation of human colon cancer cells without lysosomal storage disorder.

Abstract:

:Suramin is a polysulfonated naphthylurea currently investigated for the treatment of advanced malignancy. We have previously reported that suramin was a potent inducer of the differentiation of the human colic adenocarcinoma cell clone HT29-D4 (Fantini et al., J Biol Chem, 1989; 264: 10282-10286). In this report, we show that chronic suramin treatment of these cells is associated with a lysosomal storage disease. We have tested five suramin-related compounds for their ability to induce HT29-D4 differentiation and we looked at their action on the lysosomal apparatus. We conclude that one of the derivatives used is a more potent differentiation inducer than suramin, while it does not elicit any perturbation of the lysosomal system.

journal_name

Anticancer Drugs

journal_title

Anti-cancer drugs

authors

Baghdiguian S,Nickel P,Marvaldi J,Fantini J

doi

10.1097/00001813-199010000-00011

subject

Has Abstract

pub_date

1990-10-01 00:00:00

pages

59-66

issue

1

eissn

0959-4973

issn

1473-5741

journal_volume

1

pub_type

杂志文章
  • Artesunate inhibits the growth of gastric cancer cells through the mechanism of promoting oncosis both in vitro and in vivo.

    abstract::This study aims to investigate the significance and mechanism of artesunate involved in suppressing the proliferation of gastric cancer in vitro and in vivo. In the in-vitro experiments, artesunate inhibited the growth of gastric cancer cell lines (SGC-7901, BGC-823, and AGS) with concentration-dependent activity, wit...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328364a109

    authors: Zhou X,Sun WJ,Wang WM,Chen K,Zheng JH,Lu MD,Li PH,Zheng ZQ

    更新日期:2013-10-01 00:00:00

  • Molecular basis of hypertension side effects induced by sunitinib.

    abstract::Over the past decade a number of vascular complications have emerged, such as newly developed or worsened hypertension, in patients who were administered with new cancer treatments for several types of cancer that were untreatable earlier. Hypertension is emerging as one of the most common adverse effects of therapy w...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0b013e3283403806

    authors: Aparicio-Gallego G,Afonso-Afonso FJ,León-Mateos L,Fírvida-Pérez JL,Vázquez-Estévez S,Lázaro-Quintela M,Ramos-Vázquez M,Fernández-Calvo O,Campos-Balea B,Antón-Aparicio LM

    更新日期:2011-01-01 00:00:00

  • Novel taxanes.

    abstract::Since their addition to paclitaxel in the oncologists' armamentarium in the early 1990s, several new taxane formulations have been developed. Besides docetaxel and nab-paclitaxel, new analogs with better therapeutic profiles are being investigated. The goals of this next generation of taxanes are to improve the toxici...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0000000000000053

    authors: Muggia F,Kudlowitz D

    更新日期:2014-05-01 00:00:00

  • Phase II study of paclitaxel in pretreated advanced gastric cancer.

    abstract::Patients with advanced gastric cancer unresponsive or progressing after PELF chemotherapy (5-fluorouracil, leucovorin, cisplatin and epidoxorubicin) received paclitaxel at the dose of 225 mg/m2 every 3 weeks, over 3 h infusion. Thirty-six patients entered the study, and all of them were evaluable for response and toxi...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199804000-00003

    authors: Cascinu S,Graziano F,Cardarelli N,Marcellini M,Giordani P,Menichetti ET,Catalano G

    更新日期:1998-04-01 00:00:00

  • Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.

    abstract::Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to-agonist switch like bicalutamide. We compared the activity of ARN versus bicalutamide on prostate cancer cell lines. The 22Rv1, PC3, and DU145 cell lines were used to study the effect of ARN and b...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000592

    authors: Koukourakis MI,Kakouratos C,Kalamida D,Mitrakas A,Pouliliou S,Xanthopoulou E,Papadopoulou E,Fasoulaki V,Giatromanolaki A

    更新日期:2018-04-01 00:00:00

  • Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial.

    abstract::Mitomycin C (MMC) in combination with infusional 5-fluorouracil (5-FU) is a well-tolerated active combination therapy for advanced gastric cancer. Pegylated liposomal doxorubicin (Caelyx) has been combined with this regimen in a phase I study exhibiting promising activity in patients with upper gastrointestinal tumors...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-200504000-00010

    authors: Gnad-Vogt SU,Hofheinz RD,Saussele S,Kreil S,Willer A,Willeke F,Pilz L,Hehlmann R,Hochhaus A

    更新日期:2005-04-01 00:00:00

  • Novel mechanisms involving chemically modified tetracycline 3 cytotoxicity.

    abstract::Chemically modified tetracycline 3 (CMT-3) is a potential anticancer drug because of its retained matrix metalloproteinases inhibitory property. In the present study,we showed that CMT-3 significantly inhibited the growth and proliferation of human hepatocellular carcinoma HepG2 cells. Novel mechanisms including incre...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/cad.0000000000000144

    authors: Zhao L,Xu J,Jiao Y,Wang H,Fan S

    更新日期:2014-11-01 00:00:00

  • A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).

    abstract::In melanoma, the RAS/RAF/MEK/ERK pathway is frequently activated by mutations in BRAF and NRAS. Selumetinib (AZD6244) is an oral, selective, non-ATP-competitive inhibitor of MEK1/2. Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetin...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328350737d

    authors: Boers-Sonderen MJ,Desar IM,Blokx W,Timmer-Bonte JN,van Herpen CM

    更新日期:2012-08-01 00:00:00

  • Bufalin enhances TRAIL-induced apoptosis by redistributing death receptors in lipid rafts in breast cancer cells.

    abstract::Studies have shown that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells. However, breast cancer cells are generally resistant to TRAIL. In the present study, we explored the effect of bufalin on TRAIL-induced breast cancer cell apoptosis. The results showed...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000095

    authors: Yan S,Qu X,Xu L,Che X,Ma Y,Zhang L,Teng Y,Zou H,Liu Y

    更新日期:2014-07-01 00:00:00

  • Modulation of melphalan cytotoxic activity in human melanoma cell lines.

    abstract::The aim of the present study was to potentiate the cytotoxic effects of melphalan through pharmacological and physical modulators. The combination of the cytotoxic agent with ethacrynic acid, a glutathione-S-transferase pi (GST pi) inhibitor, or topotecan, a topoisomerase I inhibitor, or mild hyperthermia was investig...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199607000-00017

    authors: Supino R,Caserini C,Orlandi L,Zaffaroni N,Silvestrini R,Vaglini M,Zunino F

    更新日期:1996-07-01 00:00:00

  • RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo.

    abstract::RNA interference, a posttranscriptional gene-silencing mechanism, has received considerable attention for its potential as a new therapeutic strategy to treat human diseases and conditions including cancer. Various studies have supported a role for the R2 subunit of ribonucleotide reductase in cancer progression and m...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328013c04f

    authors: Avolio TM,Lee Y,Feng N,Xiong K,Jin H,Wang M,Vassilakos A,Wright J,Young A

    更新日期:2007-04-01 00:00:00

  • Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.

    abstract::Hemolytic uremic syndrome (HUS) is a rare clinical and biological entity. HUS has been reported after several anticancer chemotherapies and most often after mitomycin C-based chemotherapy regimens. Little information is available concerning the occurrence and outcome of this syndrome after administration of more recen...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199907000-00004

    authors: Gross M,Hiesse C,Kriaa F,Goldwasser F

    更新日期:1999-07-01 00:00:00

  • In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.

    abstract::Targeting of cytotoxic agents represents a modern approach to the treatment of various cancers, that improves the efficacy and reduces peripheral toxicity. Recently we developed a powerful cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AN-207, designed to be targeted to tumors that express LHRH rece...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200101000-00010

    authors: Arencibia JM,Schally AV,Halmos G,Nagy A,Kiaris H

    更新日期:2001-01-01 00:00:00

  • Apoptosis-based drug screening and detection of selective toxicity to cancer cells.

    abstract::The goal of our study was to determine whether an apoptosis assay used after short-term drug exposure could predict selective toxicity to cancer cells. To this end we compared the effect of eight anticancer drugs and 10 toxic compounds without known antitumor activity in cultures of human breast cancer cells and norma...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200308000-00008

    authors: Frankfurt OS,Krishan A

    更新日期:2003-08-01 00:00:00

  • Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models.

    abstract::Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 antibody drug, is the first-line therapy for human epidermal growth factor receptor 2-positive breast and gastric cancer. For breast cancer, the benefit of continuous treatment with trastuzumab after it becomes refractory to first-line therapy has ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000853

    authors: Shu S,Yamashita-Kashima Y,Yanagisawa M,Nakanishi H,Kodera Y,Harada N,Yoshimura Y

    更新日期:2020-03-01 00:00:00

  • Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide.

    abstract::Our previous studies have shown that arsenic trioxide (As2O3), a novel anti-cancer agent, may be active against urothelial carcinomas. A series of bladder urothelial carcinoma cells with progressive As2O3 resistance were established and studied to reveal molecular events in relation to the mechanisms of resistance to ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200409000-00007

    authors: Hour TC,Huang CY,Lin CC,Chen J,Guan JY,Lee JM,Pu YS

    更新日期:2004-09-01 00:00:00

  • Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinoma.

    abstract::A patient with platinum resistant low-grade serous ovarian carcinoma had an objective response to therapy with bevacizumab and evidence of extended activity (>7 years). This case report adds to the growing literature regarding the use of bevacizumab in low-grade serous ovarian carcinoma. ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328363b64e

    authors: Rose PG,Roma A

    更新日期:2013-10-01 00:00:00

  • A palladium(II)-saccharinate complex of terpyridine exerts higher anticancer potency and less toxicity than cisplatin in a mouse allograft model.

    abstract::The main aim of this study is to assess the safety and antitumor efficacy of a palladium(II) (Pd)-saccharinate complex with terpyridine. To characterize the Pd(II) complex in vitro, its cytotoxicity was evaluated using a water-soluble tetrazolium salt cell viability assay and the mechanism of cell death was assessed b...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000531

    authors: Cetin Y,Adiguzel Z,Polat HU,Akkoc T,Tas A,Cevatemre B,Celik G,Carikci B,Yilmaz VT,Ulukaya E,Acilan C

    更新日期:2017-09-01 00:00:00

  • The impact of taxanes on the management of genitourinary cancers.

    abstract::Taxanes have had a profound impact on the management of genitourinary tumors. In the perioperative and metastatic setting in bladder cancer, taxanes such as paclitaxel have an established role in combination chemotherapy strategies to improve survival. In metastatic prostate cancer, docetaxel was the only treatment, u...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0000000000000088

    authors: Balar AV

    更新日期:2014-05-01 00:00:00

  • Update on the current use of hormonals as therapy in advanced breast cancer.

    abstract::Hormonal agents have a confirmed role in the management of postmenopausal women with receptor-positive advanced breast cancer. Until recently, tamoxifen has been the accepted agent for treating these patients. However, accumulating evidence suggests that the new antiaromatase agents will replace the antiestrogens as t...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-200304000-00003

    authors: Vogel CL

    更新日期:2003-04-01 00:00:00

  • Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.

    abstract::Mantle cell lymphoma (MCL) remains incurable for most patients, and proteasome inhibitors like bortezomib induce responses in a minority of patients with relapsed disease. Fenretinide is a retinoid that has shown preclinical activity in B-cell lymphomas. We hypothesized that these agents could yield augmented antitumo...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000274

    authors: Cowan AJ,Frayo SL,Press OW,Palanca-Wessels MC,Pagel JM,Green DJ,Gopal AK

    更新日期:2015-10-01 00:00:00

  • Effects of bestatin (Ubenimex) on human T-cell colony formation.

    abstract::The antitumor action of bestatin is considered to be an indirect action mediated by T-cells. Therefore, we investigated the effects of bestatin on the differentiation and proliferation of human precursor T-cells using a colony formation technique. Bestatin did not increase the overall number of T-cell colonies, but it...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199102000-00005

    authors: Wakabayashi Y,Hashimoto M,Saitoh K,Osawa H,Koike M,Hirose S

    更新日期:1991-02-01 00:00:00

  • Mode of action of the novel phenazine anticancer agents XR11576 and XR5944.

    abstract::The substituted phenazines XR11576 and XR5944 were originally described as dual topoisomerase-I/II poisons. Subsequent reports, however, indicated that the association of their cytotoxicity with cellular topoisomerases was not clear. We set out to study this further using human tumour cell lines, PEO1 ovarian cancer, ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328010772f

    authors: Lewis LJ,Mistry P,Charlton PA,Thomas H,Coley HM

    更新日期:2007-02-01 00:00:00

  • Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status.

    abstract::The ONYX-015 virus is a mutated adenovirus that in theory selectively replicates and induces cytolysis in tumor cells lacking functional p53. The present study investigated whether ONYX-015 viral infection alone or in combination with conventional chemotherapeutic agents could significantly increase apoptosis in human...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:

    authors: Petit T,Davidson KK,Cerna C,Lawrence RA,Von Hoff DD,Heise C,Kirn D,Izbicka E

    更新日期:2002-01-01 00:00:00

  • Pharmacokinetics of hydroxyurea in nude mice.

    abstract::Extrachromosomal DNA is the predominant form of gene amplification in human tumors. Hydroxyurea (HU) concentrations of 100-150 microM have been promising in vitro for extrachromosomal DNA elimination. The study objective was to determine the HU dose-concentration relationship in nude mice with HU doses from 0 to 200 m...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199410000-00009

    authors: Van den Berg CL,McGill JR,Kuhn JG,Walsh JT,De La Cruz PS,Davidson KK,Wahl GM,Von Hoff DD

    更新日期:1994-10-01 00:00:00

  • Long-term exposure to MST-312 leads to telomerase reverse transcriptase overexpression in MCF-7 breast cancer cells.

    abstract::Telomerase is an enzyme responsible for telomere maintenance in almost all human cancer cells, but generally not expressed in somatic ones. Therefore, antitelomerase therapy is a potentially revolutionary therapeutic strategy, and the antitumor activity of telomerase inhibitors (TI) has been studied extensively recent...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000508

    authors: Morais KS,Guimarãesb AFR,Ramos DAR,Silva FP,de Oliveira DM

    更新日期:2017-08-01 00:00:00

  • Cisplatin microcrystals suspended in oil--toxicity in mice.

    abstract::A new dosage format, cisplatin microcrystals suspended in oil (CDDP-oil), was developed for the treatment of peritoneal carcinomatoses. We studied the acute toxicity of CDDP-oil injected intraperitoneally in mice. The 50% lethal dose was 30.3 mg/kg (27.1-33.7 mg/kg at the 95% confidence level), which was 1.79 times th...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199306000-00015

    authors: Tsujimoto H,Hagiwara A,Sakakura C,Sasaki S,Osaki K,Ohyama T,Sakakibara T,Takahashi T

    更新日期:1993-06-01 00:00:00

  • Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function.

    abstract::Hepatic and peritoneal metastases are the most frequent metastatic lesions in patients with gastrointestinal stromal tumors (GIST), and may result in intra- or extrahepatic cholestasis and altered drug metabolism. While the tyrosine kinase inhibitor imatinib, which has been recently shown to represent the treatment of...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200209000-00010

    authors: Bauer S,Hagen V,Pielken HJ,Bojko P,Seeber S,Schütte J

    更新日期:2002-09-01 00:00:00

  • Anorectal adenocarcinoma recurrence successfully treated with electrochemotherapy: a case report.

    abstract::Anal canal adenocarcinoma is generally treated like rectal cancer. Surgery is the standard treatment in early stages and neoadjuvant chemoradiation in locally advanced tumors. Local recurrences treatment paradigm often depends on the previous therapies of either surgery or radiotherapy or systemic therapy. We present ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000838

    authors: Ferioli M,Guido A,Buwenge M,Coe M,Galuppi A,de Terlizzi F,Poggioli G,Morganti AG

    更新日期:2020-01-01 00:00:00

  • Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, an in vivo study.

    abstract::Autophagy is a complex of adaptive cellular response that enhances cancer cell survival in the face of cellular stresses such as chemotherapy. Recently, chloroquine diphosphate (CQ), a widely used antimalarial drug, has been studied as a potential inhibitor of autophagy. Here, we aimed to investigate the role of CQ in...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328353f8c7

    authors: Sasaki K,Tsuno NH,Sunami E,Kawai K,Hongo K,Hiyoshi M,Kaneko M,Murono K,Tada N,Nirei T,Takahashi K,Kitayama J

    更新日期:2012-08-01 00:00:00